Aclaris Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ACRS Nasdaq 2830 www.aclaristx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aclaris Therapeutics, Inc.

Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052 - Jan 13th, 2026 5:44 am
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 - Jan 12th, 2026 4:55 am
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development - Jan 6th, 2026 4:59 am
3 Promising Penny Stocks With A Market Cap Below $400M - Dec 30th, 2025 5:05 am
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) - Dec 19th, 2025 2:01 pm
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - Nov 25th, 2025 6:00 am
Discovering Aclaris Therapeutics And Two Other Noteworthy Penny Stocks - Nov 20th, 2025 5:05 am
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates - Nov 6th, 2025 6:05 am
Aclaris: Q3 Earnings Snapshot - Nov 6th, 2025 5:08 am
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 6th, 2025 4:59 am
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates - Nov 4th, 2025 4:25 pm
Aclaris Therapeutics (NASDAQ:ACRS) adds US$40m to market cap in the past 7 days, though investors from three years ago are still down 83% - Nov 2nd, 2025 5:27 am
Aclaris Therapeutics to Participate in Three November Healthcare Conferences - Oct 29th, 2025 5:30 am
What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now? - Oct 21st, 2025 10:00 am
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth? - Oct 12th, 2025 6:49 am
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025 - Sep 30th, 2025 5:00 am
Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight - Sep 21st, 2025 7:13 am
With 56% institutional ownership, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a favorite amongst the big guns - Sep 21st, 2025 6:15 am
Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength? - Sep 18th, 2025 8:05 am
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress - Sep 9th, 2025 5:00 am